Study guide

2.10 Population Genetics, HWE & Quantitative Genetics

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

2.10 Population Genetics, HWE & Quantitative Genetics

Key Takeaways Explain This Topic AI

Under Hardy–Weinberg equilibrium (HWE), allele frequencies satisfy p + q = 1 and genotype frequencies are p² (AA), 2pq (Aa), and q² (aa).

For a rare autosomal recessive condition, disease incidence ≈ q², so the carrier frequency is approximately 2√(incidence) when q is small.

HWE assumes random mating, no selection, no migration, negligible mutation, and a large population; founder effects, assortative mating, selection, and drift violate those assumptions.

Quantitative (polygenic) traits reflect many loci of small effect plus environment; dichotomous multifactorial traits are often framed with a liability-threshold model.

Board stems commonly ask you to estimate carrier risk from incidence, recognize when HWE does not apply to a subpopulation, or distinguish Mendelian vs polygenic risk framing.

Last updated: August 2026

Why population genetics matters on the CGC exam

Domain 2 asks you to move from a family pedigree to a population-informed risk . Carrier-screening panels, ethnicity-based residual risks, and pretest counseling for recessive conditions all rest on Hardy–Weinberg equilibrium (HWE) math and on knowing when that math fails. The same domain also expects board-level comfort with quantitative genetics —polygenic inheritance, multifactorial liability, and how those concepts differ from single-gene Mendelian calculations you used in earlier sections.

On exam day, expect stems that give an incidence (for example, 1 in 2,500 births) and ask for the approximate carrier frequency , or that describe an isolated community and ask why a published population carrier rate may not apply.

Hardy–Weinberg equilibrium: definitions

For a diallelic autosomal locus with alleles A (frequency p ) and a (frequency q ):

  • Relationship Formula Meaning
  • Allele frequencies p + q = 1 All allele copies at the locus
  • Genotype frequencies at HWE p² + 2pq + q² = 1 AA, Aa, aa proportions in the population
  • Homozygous dominant p² Frequency of AA
  • Heterozygotes (carriers if recessive) 2pq Frequency of Aa
  • Homozygous recessive q² Frequency of aa (often ≈ disease incidence for AR conditions)

Key counselor translation: when a rare autosomal recessive (AR) disease is fully penetrant and diagnosed at birth, observed incidence ≈ q² . Solving for q = √(incidence) then yields the heterozygote (carrier) frequency 2pq . When the disease is rare, q is small , p ≈ 1 , and 2pq ≈ 2q = 2√(incidence) .

Worked example 1 — classic cystic fibrosis–style incidence

A Northern European population reports an AR disease incidence of 1/2,500 live births. Assume HWE, complete ascertainment, and that affected individuals are aa.

  • q² = 1/2,500 → q = 1/50 = 0.02
  • p = 1 − q = 0.98
  • Exact carrier frequency: 2pq = 2(0.98)(0.02) = 0.0392 ≈ 3.92% ≈ 1/25.5
  • Rare-disease approximation: 2q = 2/50 = 1/25 = 0.04 (4%)

Counseling use: “About 1 in 25 people in this reference population are carriers” is the approximation you will see in teaching materials; the exact 2pq is slightly lower because p is 0.98, not 1.

Worked example 2 — rarer AR condition

Incidence 1/40,000 :

  • q = √(1/40,000) = 1/200 = 0.005
  • 2pq ≈ 2q = 1/100 = 1% (exact 2pq = 2 × 0.995 × 0.005 = 0.00995 ≈ 0.995%)
  • Worked example 3 — from carrier frequency back to allele frequency

A lab brochure states carrier frequency ≈ 1/50 for a rare AR condition under HWE.

  • 2pq ≈ 1/50 = 0.02 → with p ≈ 1, q ≈ 0.01
  • Expected affected incidence q² ≈ 0.0001 = 1/10,000

This reverse calculation helps you sanity-check whether a quoted carrier rate matches a quoted incidence.

HWE assumptions (memorize as a checklist)

HWE genotype frequencies hold when the population meets these ideal conditions:

Assumption Plain-language meaning Clinical red flag if violated

Random mating Mate choice independent of genotype at the locus Consanguinity, assortative mating by phenotype/ethnicity

No selection All genotypes contribute equally to the next generation Lethal or fitness-reducing genotypes; heterozygote advantage

No migration No gene flow into/out of the population Admixture; recent immigrant subgroups

Negligible mutation Allele frequencies not shifting from new mutations each generation Dynamic mutation disorders (usually handled as special cases)

Large (effectively infinite) population Sampling error does not dominate allele-frequency change Small isolates → genetic drift and founder effects

If assumptions fail, published pan-ethnic or large-population carrier rates may misstate risk for this consultand’s ancestry or community.

  • HWE violators the board loves
  • Founder effects

A founder effect occurs when a new population is established by a small number of individuals, so allele frequencies in descendants reflect the founders’ chance genotypes—not the source population. Classic teaching examples include elevated frequencies of certain AR alleles in Ashkenazi Jewish , French Canadian , Finnish , and other founder populations. Counseling implication: use population-specific carrier frequencies and panels when available, not generic U.S. averages.

Assortative mating

Assortative mating is non-random pairing by phenotype (for example, partners who both have hearing loss, short stature, or the same cultural/religious community). Positive assortative mating increases homozygosity relative to HWE expectations and can raise the chance both partners carry the same recessive alleles. Consanguinity is a related but distinct concept: mating between relatives increases the chance of sharing alleles identical by descent .

Selection

Natural selection changes allele frequencies across generations. Heterozygote advantage (for example, sickle cell trait and malaria resistance in endemic regions) maintains deleterious alleles at higher frequency than mutation–selection balance alone would predict. Negative selection against affected homozygotes reduces q over time unless balanced by mutation or heterozygote advantage. For counseling, selection explains why some AR alleles remain common; it also warns that incidence and carrier rates are population- and environment-specific .

Genetic drift

In small populations, allele frequencies fluctuate by chance ( genetic drift ). Drift can fix or lose alleles independent of fitness. Founder effects are a drift-related phenomenon at population founding. Drift is why tiny isolates can show unexpected disease frequencies.

Migration / population stratification

Gene flow and population stratification (systematic ancestry differences between groups being compared) matter for both HWE applications and association studies (next section). A “U.S. population” rate may blend groups with very different q values, producing a number that fits no single client’s ancestry well.

Quantitative genetics basics (board level)

Not every familial trait is single-gene Mendelian. Quantitative genetics addresses traits influenced by many loci (polygenic architecture) plus environmental factors.

Concept Board-level meaning Counseling hook

Polygenic trait Many variants of individually small effect contribute additively (or with interactions) Height, many common complex diseases

Multifactorial Genes + environment jointly influence risk Neural tube defects, many congenital anomalies, common adult diseases

Heritability Proportion of phenotypic variance in a population attributable to genetic variance Does not mean “percent of this patient’s disease that is genetic”

Liability-threshold model An unseen continuous “liability” distribution; disease appears when liability exceeds a threshold Explains why recurrence risks rise with more affected relatives or more severe presentations

Polygenic risk (conceptual) Aggregate burden of risk alleles Bridges to polygenic risk scores (PRS) in the next section

Liability-threshold model — how to explain it

Imagine a bell-shaped liability curve for a dichotomous multifactorial condition (affected vs unaffected). Everyone has a liability value; only those above a threshold are affected. Relatives of an affected person have a shifted liability distribution (shared genes ± shared environment), so more of them cross the threshold—hence empiric recurrence risks higher than population incidence. Recurrence risk typically increases when:

  • More than one relative is affected
  • The affected relative is more severely affected
  • The affected relative is of the less frequently affected sex (for sex-biased thresholds)
  • The consultand is a closer relative

These qualitative rules are high-yield for CGC stems even when no numeric table is provided.

Polygenic vs Mendelian framing — avoid the trap

  • Feature Mendelian (single-gene) risk Quantitative / multifactorial risk
  • Core math Segregation ratios, Bayes, HWE carrier math Empiric risks, liability concepts, PRS (when used)
  • Typical counseling Pathogenic variant → high relative risk Modest risk shifts; population context essential

Family pattern Vertical/horizontal patterns matching inheritance Clustering without a clear single-gene pattern

Test implication Diagnostic/ predictive single-gene or panel testing Often lifestyle, screening, or research/PRS contexts

Exam scenarios and traps

Trap — using 2q when q is not small: For common “recessive” phenotypes with high q, use full 2pq , not 2q.

Trap — applying a national carrier rate to a founder community: Prefer ancestry-specific data; founder effects violate the “same q as the large population” assumption.

Trap — treating heritability as personal probability: Heritability is a population variance statistic, not an individual’s percent-genetic score.

Scenario: Incidence 1/10,000 AR disease under HWE → q = 1/100; approximate carrier frequency 1/50 . If the couple is from a known founder population with documented higher incidence, recalculate with the local incidence or use published local carrier rates.

Scenario: Two partners with the same congenital anomaly seek recurrence counseling—consider assortative mating and shared multifactorial liability, not only a single Mendelian locus.

Practice checkpoints before you move on

Convert incidence ↔ q ↔ 2pq fluently for rare AR disease.

List the five HWE assumptions and map each major violator (founder effect, assortative mating, selection, drift, migration).

Explain liability threshold in one sentence a client could follow.

State why heritability ≠ “how genetic my child’s condition is.”